Shares of Quotient Ltd. (QTNT) are losing over 12% on Monday morning after the diagnostics company reported a third-quarter loss that was wider than Wall Street analysts' estimates. Quotient also reported that the timing of its planned CE Mark submission for its Expanded Immunohematology microarray has been delayed, primarily due to various disruptions and burdens caused by the pandemic.
from RTT - Earnings https://ift.tt/2YB6tGg
via IFTTT
No comments:
Post a Comment